XTL Biopharmaceuticals Ltd.

Regulatory Filings • Dec 31, 2008

_________ false

C002��� �� �� ������������� ��"�2PublicX T L BIOPHARMACEUTICALS LTD4313Corporation no: 520039470Stock Exchange/Market: ��� �� ��1996380Hasapir 3 , Nes Ziona 76100 , ,Tel: 08-9304444 , Fax: 08-9304445E.mail address: rcohen@xtlbio.comDate of transmission: 31/12/2008              Time of broadcast: 09:50 09:42:49

Reference: 2008-02-375408

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on a 6-K form filed by the Company with SEC with regard of: 1) the Company responded in a timely fashion to the SEC request for details regarding the Company's status; and 2)The Company's CEO Mr. Ron Bentsur shall depart from the Company on or about January 31,2009.
XTL_BIOPHARMACEUTICALS_LT_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity: XENOGRAFT TECHNOLOGIES LTD
Date of revision of form structure: 16/12/2008
- - -
Name of the Signatory: : Kantor Ronen , Position of Signatory in the reporting corporation: Legal Consultant & Corporate Secretary , Name of Employer Company: .
Abba Hillel Silver Telephone: 03-6133371 , Facsimile: 03-6133372 , E-mail: rkantor@kantor-law.com 2